Malignant Fibrous Histiocytoma of Bone and Osteosarcoma: Diagnosis and Treatment — Overview, Diagnosis & Treatment Options | MyMedicPlus

Osteosarcoma is the most common primary malignant bone tumor, accounting for approximately 35% of all bone cancers, with an annual incidence of approximately 3 per million. It predominantly affects adolescents and young adults (peak incidence 10–25 years), with a second incidence peak in older adults (>65 years, usually secondary to Paget's disease or prior radiotherapy). Osteosarcoma arises most commonly in the metaphyseal region of long bones — the distal femur, proximal tibia, and proximal humerus — around the knee joint in 60% of cases. Malignant fibrous histiocytoma (MFH) of bone has been reclassified in the 2020 WHO Classification of Tumors as undifferentiated pleomorphic sarcoma (UPS) of bone — a high-grade bone sarcoma lacking specific differentiation markers, predominantly affecting adults over 40. Both are high-grade, locally destructive malignancies with significant metastatic potential — predominantly to the lungs. Modern multimodal treatment with neoadjuvant chemotherapy and limb-sparing surgery has improved 5-year survival for localized osteosarcoma to 60–80%, and limb preservation is achieved in 85–90% of patients.

The etiology of sporadic osteosarcoma involves complex chromosomal instability and dysregulation of cell-cycle checkpoints. Germline TP53 mutations (Li-Fraumeni syndrome) confer a lifetime risk of osteosarcoma exceeding 20%. Hereditary retinoblastoma (RB1 germline mutation) increases osteosarcoma risk approximately 500-fold, particularly after radiotherapy to the orbit. Rapidly growing bones — explaining the adolescent peak — are susceptible to replicative errors in osteoblasts. Prior radiation therapy at any site increases the risk of secondary osteosarcoma developing within the radiation field (latency 10–30 years). Paget's disease of bone (3% lifetime risk of sarcomatous transformation) and fibrous dysplasia are predisposing benign bone conditions. For UPS of bone: prior radiation is the most established risk factor; it can arise within an osteochondroma or other benign lesion. Anabolic steroid use, bone infarcts, and trauma (though causation is debated) have been associated with malignant bone tumor development in case series.

Pain is the cardinal symptom of both osteosarcoma and UPS of bone — initially activity-related and intermittent, progressing to constant, severe pain at rest and at night, often misattributed to 'growing pains' or sports injury in adolescents. A palpable soft-tissue mass overlying the involved bone, with warmth and erythema reflecting the hypervascularity of the tumor, develops as the disease progresses. Pathological fracture through a weakened bone occurs in 10–20% of cases and may be the presenting event for UPS of bone. Restricted joint movement and functional impairment affect the adjacent joint — 'pseudo-arthritis' from peri-articular osteosarcoma. Systemic symptoms (fever, night sweats, weight loss) are uncommon in localized disease. Pulmonary metastases — present in 15–20% at diagnosis — may cause dry cough, but most are asymptomatic and detected by surveillance CT. Alkaline phosphatase and LDH are frequently elevated and serve as surrogate tumor markers.

Plain radiograph of the affected bone demonstrates the characteristic osteosarcoma features: aggressive, permeative bone destruction; periosteal reaction (Codman's triangle; sunburst/spiculated pattern); and soft-tissue mass with ossification. MRI of the entire affected bone (including skip metastases proximal to the primary) with gadolinium is mandatory for local staging — delineating intra-medullary extent, cortical breach, neurovascular involvement, and joint involvement. CT chest is the standard for pulmonary metastasis screening (lungs being the dominant metastatic site). Bone scintigraphy or sodium fluoride PET-CT identifies skip lesions and distant bone metastases. Surgical biopsy — incisional biopsy from the soft-tissue component under the direction of the operating orthopedic oncologist — is mandatory; the biopsy tract must be excised en bloc during definitive surgery. Histopathology: osteosarcoma shows pleomorphic malignant spindle cells producing osteoid matrix; UPS shows highly pleomorphic cells without specific differentiation. Molecular profiling: no targetable mutation is standard for osteosarcoma; CDK4/MDM2 amplification analysis for dedifferentiated liposarcoma exclusion. The AJCC/UICC staging system or Musculoskeletal Tumor Society (MSTS) staging is applied.

Standard treatment for localized osteosarcoma is trimodal: neoadjuvant chemotherapy → surgical resection → adjuvant chemotherapy. MAP protocol (methotrexate 12g/m², doxorubicin 75mg/m², cisplatin 120mg/m²) is the established regimen, administered over 10 weeks pre-operatively. Pathological tumor necrosis assessment at resection — 'good response' defined as ≥90% necrosis — is the strongest prognostic factor and guides adjuvant therapy decisions. Limb-sparing resection — en-bloc excision of the tumor with wide surgical margins — is achieved in 85–90% of patients using endoprosthetic reconstruction (modular mega-prosthesis) or biological reconstruction (allograft). Amputation is reserved for patients where a wide margin cannot be achieved while preserving a functional limb, or when vascular/nerve encasement precludes reconstruction. Adjuvant chemotherapy (MAP ± ifosfamide-etoposide for poor responders) follows surgery. Pulmonary metastasectomy is performed for isolated lung metastases — 30–40% long-term survival in complete responders. UPS of bone treatment mirrors osteosarcoma: MAP-based regimens and wide resection. Denosumab is effective for giant cell tumor but not standard for osteosarcoma. Cabozantinib, sorafenib, and regorafenib have modest second-line activity in relapsed osteosarcoma.

Prognosis for osteosarcoma with modern multimodal therapy is substantially better than in the pre-chemotherapy era. Five-year overall survival for localized extremity osteosarcoma is 60–80% with neoadjuvant MAP chemotherapy and limb-sparing surgery. The most important single prognostic factor is histological tumor necrosis at resection: good responders (≥90% necrosis — Huvos Grade III–IV) achieve 5-year survival of 75–85%; poor responders (<90% necrosis) achieve 40–55%. Surgical margin adequacy is critical — positive margins are associated with greater than 50% risk of local recurrence. Metastatic disease at diagnosis — present in 15–20% — carries a 5-year survival of only 20–30%, though complete pulmonary metastasectomy in responders improves outcomes to 30–40%. Axial osteosarcoma (spine, pelvis) has worse prognosis than appendicular disease due to difficulty achieving adequate surgical margins. UPS of bone has a similar overall prognosis to osteosarcoma. Second-line agents (sorafenib, regorafenib, cabozantinib) have modest activity in relapsed osteosarcoma — 5-year survival for relapsed disease is approximately 25% with aggressive salvage approaches. Surveillance involves 3-monthly CT chest and plain radiograph of the primary site for 2 years, then every 6 months to 5 years. Limb-sparing reconstruction durability is good — 10-year implant survival exceeds 70% for modular endoprostheses, with revision surgery anticipated in most patients over time.

No strategies reliably prevent sporadic osteosarcoma. Genetic counselling is indicated for all patients under 30 with osteosarcoma, particularly when a personal or family history of retinoblastoma, Li-Fraumeni syndrome, or other TP53-related cancers is present; germline TP53 and RB1 testing is offered. Carriers of TP53 or RB1 mutations undergoing radiotherapy should minimize exposure to primary and scatter radiation to the skeleton when possible, given the heightened radio-carcinogenesis risk. Second primary sarcomas after radiotherapy can be minimized by modern conformal radiation techniques. After definitive treatment, surveillance involves 3-monthly clinic review with chest CT (for pulmonary metastases) for the first 2 years, then 6-monthly to 5 years; plain radiograph of the primary site for local recurrence; and bone scan/MRI if symptomatic. Alkaline phosphatase and LDH levels are monitored as surrogate markers of relapse.

Any persistent bone pain in an adolescent or young adult — particularly if present at rest or at night, unresponsive to simple analgesics, or associated with a palpable mass — must be investigated urgently with plain X-ray. Do not dismiss unexplained knee or shoulder pain in a teenager as 'growing pains' without radiological evaluation. A lytic or sclerotic bone lesion on plain X-ray requires urgent referral to an orthopedic oncologist — biopsy must never be performed without prior specialized imaging, as an ill-placed biopsy tract can compromise limb-sparing surgery. Pathological fracture in an adolescent or young adult through a lesion that is not clearly benign requires emergency orthopedic oncology consultation — stabilization without biopsy or internal fixation through tumor is imperative pending specialist review. Any known cancer survivor with new bone pain at a previously irradiated site should undergo imaging to exclude radiation-induced sarcoma, which may arise 10–30 years after radiation exposure.